keyword
MENU ▼
Read by QxMD icon Read
search

rituximab and lymphoma relapse

keyword
https://www.readbyqxmd.com/read/28090494/salvage-chemotherapy-with-r-bad-rituximab-bendamustine-cytarabine-and-dexamethasone-for-the-treatment-of-relapsed-primary-cns-lymphoma
#1
Min-Seok Cho, Jae Yong Kim, Seung-Yeon Jung, Seo-Yeon Ahn, Ga Young Song, Deok-Hwan Yang
No abstract text is available yet for this article.
December 2016: Blood Research
https://www.readbyqxmd.com/read/28089635/venetoclax-plus-rituximab-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-a-phase-1b-study
#2
John F Seymour, Shuo Ma, Danielle M Brander, Michael Y Choi, Jacqueline Barrientos, Matthew S Davids, Mary Ann Anderson, Anne W Beaven, Steven T Rosen, Constantine S Tam, Betty Prine, Suresh K Agarwal, Wijith Munasinghe, Ming Zhu, L Leanne Lash, Monali Desai, Elisa Cerri, Maria Verdugo, Su Young Kim, Rod A Humerickhouse, Gary B Gordon, Thomas J Kipps, Andrew W Roberts
BACKGROUND: Selective BCL2 inhibition with venetoclax has substantial activity in patients with relapsed or refractory chronic lymphocytic leukaemia. Combination therapy with rituximab enhanced activity in preclinical models. The aim of this study was to assess the safety, pharmacokinetics, and activity of venetoclax in combination with rituximab. METHODS: Adult patients with relapsed or refractory chronic lymphocytic leukaemia (according to the 2008 Modified International Workshop on CLL guidelines) or small lymphocytic lymphoma were eligible for this phase 1b, dose-escalation trial...
January 12, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28067179/cd20-based-immunotherapy-of-b-cell-derived-hematologic-malignancies
#3
Dariush Shanehbandi, Jafar Majidi, Tohid Kazemi, Behzad Baradaran, Leili Aghebati-Maleki
CD20 is a surface antigen which is expressed at certain stages of B-cell differentiation. Targeting the CD20-positive B-cells with therapeutic monoclonal antibodies (MAbs) has been an effectual strategy in the treatment of hematologic malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Initial success with Rituximab (RTX) has encouraged the creation and development of more effective CD20 based therapeutics. However, treatment with conventional MAbs has not been adequate to overcome the problems such as refractory/relapsed disease...
January 9, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28061982/pi3k-signaling-pathway-in-normal-b-cells-and-indolent-b-cell-malignancies
#4
REVIEW
Georgios Pongas, Bruce D Cheson
In chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs), B-cell receptor signaling leads to activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Idelalisib, a PI3Kδ inhibitor was approved in 2014 by the US Food and Drug Administration (FDA) in combination with rituximab for the treatment of patients with CLL for whom single-agent rituximab would be considered appropriate and as a single agent for patients with relapsed small lymphocytic lymphoma (SLL) and relapsed follicular lymphoma (FL)...
December 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/28060891/performance-of-89zr-labeled-rituximab-pet-as-an-imaging-biomarker-to-assess-cd20-targeting-a-pilot-study-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma
#5
Yvonne W S Jauw, Josée M Zijlstra, Daphne de Jong, Danielle J Vugts, Sonja Zweegman, Otto S Hoekstra, Guus A M S van Dongen, Marc C Huisman
PURPOSE: Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of 89Zirconium (89Zr)-mAb is a potential imaging biomarker for tumor targeting, since it depends on target antigen expression and accessibility. The aim of this pilot study was to describe the performance of 89Zr-labeled-rituximab-PET to assess CD20 targeting in patients with relapsed/refractory DLBCL...
2017: PloS One
https://www.readbyqxmd.com/read/28056114/diagnosis-and-management-of-waldenstr%C3%A3-m-macroglobulinemia-mayo-stratification-of-macroglobulinemia-and-risk-adapted-therapy-msmart-guidelines-2016
#6
Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, Asher Chanan-Khan, Robert A Kyle, Shaji K Kumar, Joseph R Mikhael, Thomas E Witzig, Michelle Mauermann, Angela Dispenzieri, Sikander Ailawadhi, A Keith Stewart, Martha Q Lacy, Carrie A Thompson, Francis K Buadi, David Dingli, William G Morice, Ronald S Go, Dragan Jevremovic, Taimur Sher, Rebecca L King, Esteban Braggio, Ann Novak, Vivek Roy, Rhett P Ketterling, Patricia T Greipp, Martha Grogan, Ivana N Micallef, P Leif Bergsagel, Joseph P Colgan, Nelson Leung, Wilson I Gonsalves, Yi Lin, David J Inwards, Suzanne R Hayman, Grzegorz S Nowakowski, Patrick B Johnston, Steven J Russell, Svetomir N Markovic, Steven R Zeldenrust, Yi L Hwa, John A Lust, Luis F Porrata, Thomas M Habermann, S Vincent Rajkumar, Morie A Gertz, Craig B Reeder
Importance: Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years. With availability of a wider array of therapies, the management strategies have become increasingly complex. Our multidisciplinary team appraised studies published or presented up to December 2015 to provide consensus recommendations for a risk-adapted approach to WM, using a grading system. Observations: Waldenström macroglobulinemia remains a rare, incurable cancer, with a heterogeneous disease course...
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28050137/emerging-therapies-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma
#7
REVIEW
D MacDonald, A Prica, S Assouline, A Christofides, T Lawrence, L H Sehn
With no treatment standard having been established for relapsed and refractory follicular lymphoma, a number of therapeutic approaches are used in Canada. In patients who relapse early or who eventually become resistant to subsequent treatment, prognosis is poor, and new approaches are needed. A number of novel therapies are being examined in this setting, including monoclonal antibodies, immunoconjugates, immunomodulatory agents, and signal transduction inhibitors. With the body of evidence for those emerging therapies accumulating and the standard upfront treatment changing from rituximab and chop (cyclophosphamide-doxorubicin-vincristine-prednisone) or rituximab and cvp (cyclophosphamide-vincristine-prednisone) to bendamustine and rituximab, treatment decisions in the relapsed and refractory setting have become more complex...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28039906/prognostic-impact-of-cd5-expression-in-diffuse-large-b-cell-lymphoma-in-patients-treated-with-rituximab-epoch
#8
Beenu Thakral, L Jeffrey Medeiros, Parth Desai, Pei Lin, C Cameron Yin, Guilin Tang, Joseph D Khoury, Shimin Hu, Jie Xu, Sanam Loghavi, Bei Hu, Yasuhiro Oki, Shaoying Li
OBJECTIVES: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) represents 5-10% of all DLBCL cases, which has been associated with a poorer prognosis in patients treated with R-CHOP. Prognostic impact of CD5 expression in DLBCL patients treated with R-EPOCH has not been evaluated. METHODS: We studied 130 patients with de novo DLBCL who received frontline R-EPOCH therapy. The clinicopathologic features and overall survival (OS) were compared between the CD5+ and CD5-negative DLBCL patients...
December 31, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/28039708/clinical-implications-of-glutathione-s-transferase-genotyping-in-patients-with-diffuse-large-b-cell-lymphoma
#9
Lavinika Atanaskovic, Bojana Cikota-Aleksic, Olivera Tarabar, Jovana Trimcev, Andelina Zivanovic-Ivic, Slobodan Marjanovic, Zvonko Magic
PURPOSE: Polymorphic deletions in glutathione S-transferase (GST) genes are recognized as a risk factor for lymphoma, other hematological and non-hematological malignancies. The purpose of the present study was to investigate whether deletions of GSTT1 and GSTM1 as well as GSTP1 Ile- 105Val single nucleotide polymorphism influence clinical presentation, response to therapy and outcome in patients with diffuse large B-cell lymphoma (DLBCL). METHODS: The study included a total of 82 DLBCL patients treated with rituximab-CHOP (R-CHOP) therapy (6-8 cycles)...
November 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28039078/molecular-monitoring-after-autologous-stem-cell-transplantation-and-preemptive-rituximab-treatment-of-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-8-5-years
#10
Arne Kolstad, Lone Bredo Pedersen, Christian W Eskelund, Simon Husby, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, Niels Smedegaard Andersen, Peter deNully Brown, Eva Kimby, Hans Bentzen, Christer Sundström, Mats Ehinger, Marja-Liisa Karjalainen-Lindsberg, Jan Delabie, Elisabeth Ralfkiær, Unn-Merete Fagerli, Herman Nilsson-Ehle, Grete Fossum Lauritzsen, Outi Kuittinen, Carsten Niemann, Christian Hartman Geisler
The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in the our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rearrangements...
December 27, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28029326/ofatumumab-versus-rituximab-salvage-chemoimmunotherapy-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-the-orcharrd-study
#11
Gustaaf W van Imhoff, Andrew McMillan, Matthew J Matasar, John Radford, Kirit M Ardeshna, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, Sirpa Leppä, Michael Fennessy, Qiming Liao, Bronno van der Holt, Steen Lisby, Anton Hagenbeek
Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by autologous stem-cell transplantation (ASCT) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients with CD20(+) DLBCL age ≥ 18 years who had experienced their first relapse or who were refractory to first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like treatment were randomly assigned between three cycles of R-DHAP or O-DHAP...
December 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28004881/efficacy-and-toxicity-of-pacebom-chemotherapy-in-relapsed-refractory-aggressive-lymphoma-in-the-rituximab-era
#12
Babak Tamjid, Joseph Mckendrick, Anthony Schwarer, Rowan Doig, Philip James, Patrick Hosking, Eliza A Hawkes
AIM: Relapsed/refractory (R/R) aggressive lymphoma outcomes are poor. There is no standard treatment. PACEBOM (prednisolone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine and methotrexate) has shown efficacy for several lymphoma subtypes in published reports. We evaluate PACEBOM+/-rituximab for R/R aggressive lymphomas in this millennium. METHODS: In this retrospective, single-center study, R/R aggressive lymphoma patients who received PACEBOM or its derivatives were identified from the pharmacy database...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004361/a-review-of-obinutuzumab-ga101-a-novel-type-ii-anti-cd20-monoclonal-antibody-for-the-treatment-of-patients-with-b-cell-malignancies
#13
REVIEW
Kensei Tobinai, Christian Klein, Naoko Oya, Günter Fingerle-Rowson
Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. Obinutuzumab has a distinct mode of action relative to type I anti-CD20 antibodies, such as rituximab, working primarily by inducing direct cell death and antibody-dependent cell-mediated cytotoxicity. Obinutuzumab is under investigation in a wide-ranging program of clinical trials in patients with B-cell malignancies...
December 21, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27998707/late-relapses-after-high-dose-chemotherapy-and-autologous-stem-cell-transplantation-in-patients-with-diffuse-large-b-cell-lymphoma-in-the-rituximab-era
#14
Bradley D Hunter, Megan Herr, Philip J Meacham, Ferdous Barlaskar, Andrew G Evans, W Richard Burack, Jane L Liesveld, Michael W Becker, Laurie A Milner, Louis S Constine, Sughosh Dhakal, Paul M Barr, Jonathan W Friedberg, Carla Casulo
BACKGROUND: The standard of care for diffuse large B-cell lymphoma (DLBCL) relapsing after front-line therapy is high-dose chemotherapy and autologous stem cell transplantation (ASCT). Evidence has suggested that early relapses (ie, within 1 year) after this approach portends exceptionally poor outcomes. However, data examining relapses > 1 year after ASCT for patients with refractory or relapsed DLBCL are limited, in particular, in the rituximab era. We sought to examine the effect of early (≤ 1 year) and late (> 1 year) relapse after ASCT in a single-institution cohort of patients with relapsed and refractory DLBCL treated with chemoimmunotherapy...
November 23, 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27990323/impaired-functional-responses-in-follicular-lymphoma-cd8-tim-3-t-lymphocytes-following-tcr-engagement
#15
Pauline Gravelle, Catherine Do, Camille Franchet, Sabina Mueller, Lucie Oberic, Loïc Ysebaert, Luigi Maria Larocca, Stefan Hohaus, Marie-Noëlle Calmels, François-Xavier Frenois, Robert Kridel, Randy D Gascoyne, Guy Laurent, Pierre Brousset, Salvatore Valitutti, Camille Laurent
Upregulation of T cell immunoglobulin-3 (TIM-3) has been associated with negative regulation of the immune response in chronic infection and cancer, including lymphoma. Here, we investigated the possible correlation between TIM-3 expression by ex vivo cytotoxic T cells (CTL) from follicular lymphoma (FL) biopsies and their functional unresponsiveness that could limit the favorable impact of CTL on disease progression. We report a high percentage of CD8(+)TIM-3(+)T cells in lymph nodes of FL patients. When compared to their CD8(+)TIM-3(-) counterparts, CD8(+)TIM-3(+) T cells exhibited defective cytokine production following TCR engagement...
2016: Oncoimmunology
https://www.readbyqxmd.com/read/27986884/beyond-rchop-a-blueprint-for-diffuse-large-b-cell-lymphoma-research
#16
REVIEW
Grzegorz S Nowakowski, Kristie A Blum, Brad S Kahl, Jonathan W Friedberg, Lawrence Baizer, Richard F Little, David G Maloney, Laurie H Sehn, Michael E Williams, Wyndham H Wilson, John P Leonard, Sonali M Smith
Diffuse large B cell lymphoma (DLBCL) comprises multiple molecular and biological subtypes, resulting in a broad range of clinical outcomes. With standard chemoimmunotherapy, there remains an unacceptably high treatment failure rate in certain DLBCL subsets: activated B cell (ABC) DLBCL, double-hit lymphoma defined by the dual translocation of MYC and BCL2, dual protein-expressing lymphomas defined by the overexpression of MYC and BCL2, and older patients and those with central nervous system involvement. The main research challenges for DLBCL are to accurately identify molecular subsets and to determine if specific chemotherapy platforms and targeted agents offer differential benefit...
December 2016: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/27986437/intralesional-rituximab-in-primary-conjunctival-follicular-lymphoma-relapsed
#17
S Rodríguez Villa, M J Ruiz Rodríguez, M Vargas Pabón
CLINICAL CASE: A 49-year-old woman experienced a local relapse of a primary follicular lymphoma (FL) of the conjunctiva. She received 4 weekly intra-lesional injections followed by 6 monthly injections of rituximab (6mg/ml). A clinical response was achieved after first injection. No adverse ocular event or signs of lymphoma relapse were seen after 10 months of follow-up. DISCUSSION: Intralesional administration of rituximab for treating primary FL of the conjunctiva was an effective and safe therapeutic option; therefore it could be an alternative to other conventional treatments, such as radiotherapy or chemotherapy...
December 13, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/27982454/relationship-between-venetoclax-exposure-rituximab-coadministration-and-progression-free-survival-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-demonstration-of-synergy
#18
Kevin J Freise, Aksana K Jones, Rajeev M Menon, Maria E Verdugo, Rod A Humerickhouse, Walid M Awni, Ahmed Hamed Salem
Venetoclax is indicated at a dosage of 400 mg daily (QD) for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least 1 prior therapy. Ongoing trials are evaluating venetoclax in combination with CD20 targeting monoclonal antibodies, such as rituximab. The objective of this research was to characterize the relationship between venetoclax exposures and progression-free survival (PFS) and to evaluate the effect of rituximab coadministration on PFS in patients with relapsed or refractory (R/R) CLL/small lymphocytic lymphoma (SLL)...
December 16, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27982423/outcomes-of-primary-refractory-diffuse-large-b-cell-lymphoma-dlbcl-treated-with-salvage-chemotherapy-and-intention-to-transplant-in-the-rituximab-era
#19
Santosha A Vardhana, Craig S Sauter, Matthew J Matasar, Andrew D Zelenetz, Natasha Galasso, Kaitlin M Woo, Zhigang Zhang, Craig H Moskowitz
Rituximab-containing salvage chemotherapy followed by high-dose therapy and autologous stem cell transplant (ASCT) in chemosensitive patients remains the standard of care for patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, its role in those patients achieving less than a complete response to first-line therapy (primary refractory disease) in the rituximab era is not well defined. We reviewed the outcomes of 82 transplant-eligible patients with primary refractory DLBCL who underwent salvage therapy with the intent of administering high-dose therapy and ASCT to patients achieving chemosensitive remission...
December 16, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27979923/efficacy-and-safety-of-idelalisib-in-patients-with-relapsed-rituximab-and-alkylating-agent-refractory-follicular-lymphoma-a-subgroup-analysis-of-a-phase-2-study
#20
Gilles Salles, Stephen J Schuster, Sven de Vos, Nina D Wagner-Johnston, Andreas Viardot, Kristie A Blum, Christopher R Flowers, Wojciech J Jurczak, Ian W Flinn, Brad S Kahl, Peter Martin, Yeonhee Kim, Sanatan Shreay, Matthias Will, Bess Sorensen, Madlaina Breuleux, Pier Luigi Zinzani, Ajay K Gopal
No abstract text is available yet for this article.
December 15, 2016: Haematologica
keyword
keyword
114416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"